Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T : +91 40 2726 4141 F : +91 40 2726 3657



VLL\10\S-004\2021\ Date: 22.07.2021

Listing Centre B S E Limited P J Towers, Dalal Street Mumbai: 400001 Scrip Code No.524394 Asst Vice President National Stock Exchange of India Limited "Exchange Plaza", Bandra Kurla Complex, Bandra (E) Mumbai – 400051 **Trading Symbol: VIMTALABS**

Dear Sirs,

Sub – Outcome of the Board Meeting.

Pursuant to Regulation 33 and 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find enclosed herewith Standalone and Consolidated Unaudited Financial Results for the 1st quarter ended 30th June 2021, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company's website i.e., <u>http://www.vimta.com/financials</u>. Abridged financials are being published in the newspapers (copy enclosed).

The meeting commenced at 10:00 AM and ended at 11:30 AM

This is for your information and records.

Thanking you,

Yours faithfully. for VIMTA LA ABION Sujani Vasired Company Secre

Encl: as above.

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

GATTAMANENI & CO. CHARTERED ACCOUNTANTS

Limited Review Report on Unaudited Standalone Quarterly Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

- 1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company'), for the quarter ended 30 June 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SFBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

for GATTAMANENI & CO. Chartered Accountants (Firm Regn.No.9203S)

Place: Hyderabad Date: 22-07-2021

G. SRAIVASARAO Partner ICAI Ms. No.2105351/ UDIN: 21210535AAAAEL4840 * (F.R.No. 93. RED AC

Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, Telangana, India T : +91 40 2726 4141 F : +91 40 2726 3657



1

Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2021

(Amount in INR millions, except Earnings Per Share)

S. No.			Year Ended		
	Particulars	30 Jun 21 (Unaudited)	31 Mar 21 (Audited)	30 Jun 20 (Unaudited)	31 Mar 21 (Audited)
1	Income from operations				
1	(a) Revenue from operations	C10.01	104.00	225 60	
	(b) Other income	610.05	594.93	325.68	2.090.51
		1.81	2.38	2.31	8 10
	Total Income	611 86	597.31	327.99	2,098.6
2	Expenses				
	(a) Cost of materials consumed and testing	171.45	167.23	87.97	578.5
	expenditure			8	
	(b) Purchase of stock-in-trade	-	-	-	_
	(c) Changes in inventories of work-in-progress	1.10	0.59	10.21	29.8
	(d) Employee benefits expense	180.46	163.27	128.14	
	(e) Finance costs			1000000000	602.5
	(f) Depreciation expense	4.32	6.78	5.91	21.6
		54.93	57.87	56.39	229.3
	(g) Other expenses	90.17	97.24	62.78	352.6
	Total Expenses	502.43	492.98	351.40	1,814.64
3	Profit/(Loss) before exceptional items and tax [1-2]	109.43	104.33	(23.41)	283.97
4	Exceptional items	-	·		
5	Profit/(Loss) before tax [3-4]	109.43	104.33	(23.41)	283.97
	-				
6	Tax expense				
	(a) Current tax	33.84	22.06	-	76.26
	(b) Deferred tax (benefit)/expense	(5.46)	4.80	(4.66)	(4.89
	Total Tax Expense	28.38	26.86	(4.66)	71.37
7	Profit/(Loss) for the period (5-6)	81.05	77.47	(18.75)	212.60
	Other Comprehensive Income/(expense), net of tax expenses				
	Items that will not be reclassified subsequently to profit or loss :				
	(a) Re-measurements of net defined benefit liability	0.55	3.29	(0.65)	1.34
	(b) Income tax relating to the items	(0.14)	(0.83)	0.16	(0.34
	Total other comprehensive income/(loss), net of tax	0.41	2.46	(0.49)	1.00
9	Tatal Companyation losses (an its second				
	Total Comprehensive Income for the period	81.46	79.93	(19.24)	213.60
	(comprising Profit/(Loss) and other Comprehensive income for the period [7+8]				
	Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)	44.22	44.22	44.22	44.2
11	Other Equity				1,898.97
	Earnings per equity share (EPS) (Face value of Rs.2 per share)				
	a) Basic (INR)	2.67	2.50	10.05	
		3.67	3.50	(0.85)	9.6
	b) Diluted (INR)	3.67	3.50	(0.85)	9.6
(EPS for the quarter ended are not annualised)				
	-				

Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India C T : +91 40 6740 4040 E : mdoffice@vimta.com

Notes to the results :

- 1 The above unaudited standalone financial results for the quarter ended June 30, 2021 have been reviewed by the Audit Committee held on July 21, 2021 and are approved by the Board in its meeting held on July 22, 2021.
- 2 The results for the quarter ended 30th June 2021 were subjected to 'limited review' by the statutory auditors of the company. An unqualified report was issued there on.
- 3 These unaudited standalone financials results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 4 The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Company has only one reportable segment namely 'Contract Research and Testing Services'.
- 5 The Company has considered internal and external information upto the date of approval of these standalone financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these standalone financial results.
- 6 The shareholders of the company have approved Employee Stock Option Plan 2021 in its meeting held on July 5, 2021 and the same is being processed by the Nomination and Remuneration Committee.
- 7 The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/period.

For and on behalf of the Board of Directors of Vinta Labs Limited

CIN: L24110TG1990PLC Harita Vasireddi Managing Director ERABI

Place : Hyderabad, INDIA Date : July 22, 2021





Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2021 (Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Year ended	
		30 Jun 21	31 Mar 21	30 Jun 20	31 Mar 21	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Total Income from Operations	610.05	594.93	225 60	2 000 51	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	201 BURN (2012)	104.33	325.68 (23.41)	2,090.51 283.97	
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	109.43	104.33	(23.41)	283.97	
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	81.05	77.47	(18.75)	212.60	
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]		79.93	(19.24)	213.60	
6 7	Equity Share Capital Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	44.22	44.22	44.22	44.22 1,898.97	
8	Earnings Per Share (of Rs.2/- each) (for continuing and discontinued Operations) 1. Basic (INR) 2. Diluted (INR)	3.67 3.67	3.50 3.50	(0.85) (0.85)	9.62 9.62	

Note :

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).

- 2 The above unaudited standalone financial results of the company for the quarter ended June 30, 2021 have been reviewed by the Audit Committee on July 21, 2021 and approved by the Board of Directors at their meeting held on July 22, 2021
- 3 Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of Vimta Labs Limited



Place : Hyderabad, INDIA Date : July 22, 2021



Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

CIN: L24110TG1990PLC011977

GATTAMANENI & CO. CHARTERED ACCOUNTANTS

Limited Review Report on Unaudited Consolidated Quarterly Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Holding Company') and M/s.EMTAC Laboratories Private Limited, wholly owned subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended 30 June 2021, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

We also performed procedures in accordance with Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 22-07-2021

for GATTAMANENI & CO. Chartered Accountants (Firm Regn.No.9303S) G. SRINIVASARAC Partner ICAI Ms. No.210535 UDIN: 21210535AAAAEM9903 ED ACC



Ouarter Ended Year ended S. No. Particulars 30 Jun 21 31 Mar 21 30 Jun 20 31 Mar 21 (Unaudited) (Audited) (Unaudited) (Audited) 1 Income from operations (a) Revenue from operations 613.54 598.42 327.80 2,106.79 (b) Other income 2 35 1.75 2.35 8 29 Total Income 615.29 600 77 330 15 2,115.08 Expenses 2 (a) Cost of materials consumed and testing 171.98 167.63 88.40 581.30 expenditure (b) Purchase of stock-in-trade (c) Changes in inventories of work-in-progress 1.10 0.59 10.21 29.84 (d) Employee benefits expense 181.72 164.75 129.12 607.78 (e) Finance costs 4.32 6.79 5.91 21 68 (f) Depreciation expense 55.38 58.24 230.78 56.73 (g) Other expenses 91.77 98.56 63.86 358.30 **Total Expenses** 506.27 496.56 354.23 1,829.68 3 Profit/(Loss) before exceptional items and tax [1-109.02 104.21 (24.08) 285.40 21 Exceptional items 4 5 Profit/(Loss) before tax [3-4] 109.02 104.21 (24.08) 285.40 6 Tax expense (a) Current tax 33.84 22.06 76.26 (b) Deferred tax (benefit)/expense (5.52) (4.65) 4.73 (4.91)Total Tax Expense 28.32 26.79 (4.65) 71.35 7 Profit/(Loss) for the period (5-6) 80.70 77.42 (19.43) 214.05 8 Other Comprehensive Income/(expense), net of tax expenses Items that will not be reclassified subsequently to profit or loss : (a) Re-measurements of net defined benefit 0.55 3.29 (0.65) 1.34 liability (b) Income tax relating to the items (0.14)(0.82) 0.16 (0.34) Total other comprehensive income/(loss), net of 0.41 (0.49) 2.47 1.00 tax Total Comprehensive Income for the period 9 81.11 79.89 (19.92) 215.05 (comprising Profit/(Loss) and other Comprehensive income for the period [7+8] 10 Paid-up Equity Share Capital (Face value of Rs.2/-44.22 44.22 44.22 44.22 per equity share) 11 Other Equity 1,899.60 12 Earnings per equity share (EPS) (Face value of Rs.2 per share) (a) Basic (INR) 3.65 3.50 (0.88) 9.68 (b) Diluted (INR) 3.65 3.50 (0.88) 9.68 (EPS for the guarter ended are not annualised)

Statement of Unaudited Consolidated Financial Results for the Quarter Ended June 30, 2021 (Amount in INR millions, except Earnings Per Share)




Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamper, Hyderabad - 500 101, Telangana, India T: +91 40 6740 4040 E: mdoffice@vimta.com URL: www.vimta.com

CIN: L24110TG1990PLC011977

Notes to the results :

- 1 The above unaudited consolidated financial results for the quarter ended June 30, 2021 have been reviewed by the Audit Committee on July 21, 2021 and approved by the Board in its meeting held on July 22, 2021.
- 2 The results for the quarter ended 30th June 2021 were subjected to 'limited review' by the statutory auditors of the company. An unqualified report was issued there on.
- 3 These unaudited consolidated financials results of the Group are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 4 The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'.
- 5 The Group has considered internal and external information upto the date of approval of these consolidated financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these consolidated financial results.
- 6 The shareholders of the company have approved Employee Stock Option Plan 2021 in its meeting held on July 5, 2021 and the same is being processed by the Nomination and Remuneration Committee.
- 7 The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/period.





P



Statement of Unaudited Consolidated Financial Results for the Quarter Ended June 30, 2021 (Amount in INR millions, except Earnings Per Share)

S. No.	Particulars		Year ended		
		30 Jun 21 (Unaudited)	31 Mar 21 (Audited)	30 Jun 20 (Unaudited)	31 Mar 21 (Audited)
1	Total Income from Operations	613.54	598.42	327.80	2,106.7
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	109.02	104.21	(24.08)	285.4
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	109.02	104.21	(24.08)	285.4
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	80.70	77.42	(19.43)	214.0
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	81.11	79.89	(19.92)	215.0
6	Equity Share Capital	44.22	44.22	44.22	44.2
	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year Earnings Per Share (of Rs.2/- each) (for			· · · · · · · · · · · · · · · · · · ·	1,899.6
J	continuing and discontinued Operations) 1. Basic (INR)	3.65	3.50	(0.88)	9.6
	2. Diluted (INR)	3.65	3.50	(0.88)	9.6

Note :

- 1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website (www.vimta.com) and on the websites of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
- 2 The above unaudited consolidated financial results of the group for the quarter ended June 30, 2021 have been reviewed by the Audit Committee on July 21, 2021, approved by the Board of Directors at their meeting held on July 22, 2021.
- 3 Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of Vimta Labs Limited CIN: L24110TG1999PLC011977 Harita Vasireddi Managing Director

Place : Hyderabad, INDIA Date : July 22, 2021



Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

CIN: L24110TG1990PLC011977